Blackstone (BX.N) is exploring a sale of medical-grade skincare brand ZO Skin Health at a roughly $2 billion valuation, signaling renewed private-equity appetite for clinically backed consumer health assets.
A deal at that figure would underscore how strongly strategic buyers are pricing the defensible distribution moat that physician-only skincare labels command over mass-market alternatives – a premium that could set a comparable benchmark across the broader prestige dermatology segment.
Key Takeaways
- Blackstone is running an early-stage sale process for ZO Skin Health.
- Indicative valuation sits at approximately $2 billion.
- Citigroup and Raymond James are advising on the transaction.
Market Reaction & Context
Blackstone (BX.N) shares were trading in a broadly stable range on Monday, with the ZO news adding incremental color to the firm’s ongoing portfolio-monetization cycle rather than shifting sentiment materially. The reported $2 billion price tag places ZO Skin Health in the upper tier of specialty skincare transactions, a segment where deals have increasingly commanded double-digit EBITDA multiples as strategic acquirers compete for physician-distributed brands with locked-in, recurring revenue from clinical channels 1.
The announcement lands alongside a parallel sale process for Dr Teal’s parent company – also pegged at roughly $2 billion – reinforcing that private-equity sponsors are simultaneously clearing consumer-health positions into what appears to be a receptive M&A window.
About ZO Skin Health
Dermatologist Dr. Zein Obagi founded ZO Skin Health in 2007, building the brand around a physician-distributed model that restricts retail access and anchors credibility in clinical outcomes. The company’s portfolio spans cleansers, serums, exfoliators, and toners, all sold exclusively through physicians and licensed skincare professionals – a go-to-market design that limits commoditization pressure and supports premium pricing 1.
That distribution architecture is precisely what buyers are paying up for. Strategic acquirers across beauty, pharma, and healthcare are prioritizing clinically backed brands because their demand profile is more durable than over-the-counter products, which face greater exposure to consumer-sentiment swings and private-label substitution.
Deal Structure & Advisers
Blackstone is working with bankers at Citigroup (C.N) and Raymond James (RJF.N) to run the process, according to people familiar with the matter who requested anonymity because the talks are private 1. The process is described as early-stage, meaning indicative bids and formal data-room access are likely weeks away.
Blackstone and Citi declined to comment; ZO Skin Health and Raymond James did not immediately respond to requests for comment, Reuters said.
Outlook & Analyst Framing
“Many strategic buyers are prioritizing clinically backed, physician-distributed skincare brands like ZO because of their efficacy and steadier demand versus over-the-counter products,” according to sources cited by Reuters familiar with the sale rationale 1.
That framing positions ZO as a strategic fit for large beauty conglomerates – such as L’Oréal, Estée Lauder, or Galderma – as well as for healthcare-oriented strategics seeking consumer-facing dermatology platforms. Activist interest from financial sponsors circling dermatology roll-ups could also add competitive tension to the bidding.
Conclusion
A completed deal near the $2 billion mark would rank among the larger specialty skincare exits in recent memory and add pressure on rivals holding comparable physician-channel assets to reassess their own strategic options. For BX investors, the sale represents another step in the firm’s broader effort to crystallize value from its consumer and healthcare holdings – a theme that is likely to remain active through year-end.
Not investment advice. For informational purposes only.
References
1Summerville, Abigail (2026-09-08). “Blackstone explores sale of ZO Skin Health, sources say”. Reuters. Retrieved September 9, 2026.